Navigation Links
Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway

and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases. The first FDA approved product to use this nab platform, ABRAXANE(R), was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on The Nasdaq Global Market under the symbol ABBI. For more information about the company and its products, please visit www.abraxisbio.com.

FORWARD-LOOKING STATEMENT

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the timing and scope of clinical studies and trials for nab-rapamycin mTOR inhibitor (ABI 009), and nab-17AAG HSP90 inhibitor (ABI 010). Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward- looking statements. These factors include, without limitation, the fact that results from pre-clinical studies may not be predictive of results to be obtained in other pre-clinical studies or future clinical trials, delays in commencement and completion of clinical trials, including slower than anticipated patient enrollment and adverse events occurring during the clinical trials, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the availability and pricing of ingredients used in the manufacture of pharmaceutical products, the ability to successfully manufacture products in a time-sensitive and cost effective manner, the acceptance and demand of
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
2. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
Post Your Comments:
(Date:7/11/2014)... July 11, 2014 Research and Markets ... and Chinese Medical X-ray Film Industry Report 2014" ... http://photos.prnewswire.com/prnh/20130307/600769 Global And Chinese Medical X-Ray ... study on the current state of the Global medical ... situation. The report provides a basic overview of ...
(Date:7/11/2014)... , July 11, 2014  Kindred Hospital ... to announce the opening of its new outpatient ... outpatient services to people with chronic, hard to ... which can lead to amputation, lower leg wounds ... have delayed closure, and traumatic injury wounds which ...
(Date:7/11/2014)... , July 11, 2014 According ... Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, and ... Trends and Forecast, 2013-2019" the global endoscopy devices market ... is expected to grow at a CAGR of 6.8% ... of USD 36.9 billion in 2019. Browse ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6
... , , , ... SAN DIEGO, Sept. 18, 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ... BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) trial. BLOSSOM ... for Overweight and Obesity Management) trial and completes the lorcaserin Phase 3 ...
... , NEWNAN, Ga., Sept. 16 CeloNova ... make two presentations at the Cardiovascular and Interventional Radiology Society ... excellent clinical results in treating liver cancer. Professor Orsi and ... Italy have developed a technique to cut off the blood ...
Cached Medicine Technology:Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 2Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 3Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 4Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 5Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 6Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 7Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 8Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 9Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 10Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 11Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December 12New Micro-Bland Embolization Technique with Embozene(TM) Microspheres to Be Presented at the International Medical Conference in Lisbon, Portugal 2
(Date:7/14/2014)... NC (PRWEB) July 14, 2014 The ... the University of Pennsylvania to fund a clinical trial ... here to read Surviving Mesothelioma’s newly-posted article on ... plan to use the grant to enroll 102 ... years. Patients will receive a photosensitizing drug prior to ...
(Date:7/14/2014)... SC (PRWEB) July 14, 2014 Many diet ... a study by the School of Public Health at ... vegetable consumption had a near-zero effect on weight loss. Now ... be combine with some form of portion control ... method of monitoring portions and controlling how much is consumed, ...
(Date:7/14/2014)... Washington DC (PRWEB) July 14, 2014 ... MessageSolution, an industry leader and Microsoft gold partner will ... network with Microsoft partners from the world and to ... all Microsoft platforms of Exchange email server, Office 365, ... DC from July 13 to 17, 2014. , “In ...
(Date:7/14/2014)... NATURALLY, DANNY SEO, a new magazine ... with a Fall issue that hits newsstands nationwide on ... the healthy, natural and good for you life with ... beauty, travel, home, and entertaining all through Danny’s unique ... “Instead of gimmicky weight loss tips and fluffy celebrity ...
(Date:7/14/2014)... San Diego, CA (PRWEB) July 14, 2014 ... website daily regarding all the latest information from the ... Injection . , The FDA informed on July 11, ... Injection, USP, 1000 mL, Flexible Container, by Hospira Inc., ... is used for parenteral replacement of extracellular losses of ...
Breaking Medicine News(10 mins):Health News:New Research Could Expand Availability of Light-Based Mesothelioma Therapy, According to Surviving Mesothelioma 2Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 2Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 3Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 2Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 3Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 4Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 5Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 2Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 3Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 4Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 5Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 6Health News:Hospira Lactated Ringer’s and 5% Dextrose Injection Recalled: AttorneyOne Monitor and Keep Consumers Informed 2Health News:Hospira Lactated Ringer’s and 5% Dextrose Injection Recalled: AttorneyOne Monitor and Keep Consumers Informed 3
... clinical trials, design may also mask risk of HIV drug ... new study questions whether vaginal microbicides being developed to help ... resistance from the virus that causes AIDS. , The ... Proceedings of the National Academy of Sciences , also shows ...
... anti-seizure drugs that showed double the risk , , THURSDAY, ... cause increased suicidal tendencies in patients, a U.S. health ... experts voted unanimously to back the findings on 11 ... Administration, the Associated Press reported. , In ...
... WASHINGTON, July 10 Two leading U.S. House,Judiciary Committee ... Judiciary Committee and Rep. Lamar Smith, ranking member of ... B. Mukasey to,have the Department of Justice focus its ... seeking to gain control of,U.S. copper miner ASARCO., ...
... 2008 -- Later this month, thousands of scientists and health ... the 50th meeting of the American Association of Physicists in ... July 31, they will present the latest technologies for imaging ... facing the field today. , Whether X-rays for CT ...
... of a noisy Chicago restaurant during the breakfast rush ... many voices was the crucial test of new hearing ... University School of Medicine in St. Louis. The study showed ... the most challenging test for a hearing aid. ,But ...
... Va., July 10 Axiom Resource,Management, Inc., has been ... the field of healthcare information and technology. Healthcare,Informatics magazine ... June, 2008, ranking Axiom at number 76. Axiom moved ... at number 81 on the list., Axiom managing ...
Cached Medicine News:Health News:Vaginal Microbicides Might Help More Men Than Women 2Health News:Epilepsy Drugs Can Cause Suicidal Tendencies, FDA Panel Finds 2Health News:Epilepsy Drugs Can Cause Suicidal Tendencies, FDA Panel Finds 3Health News:Chair, Ranking Member of U.S. House Judiciary Committee Urge DOJ to do 'Careful Study' of Environmental Record of Vedanta/Sterlite, Other Would-Be Buyers of ASARCO 2Health News:Chair, Ranking Member of U.S. House Judiciary Committee Urge DOJ to do 'Careful Study' of Environmental Record of Vedanta/Sterlite, Other Would-Be Buyers of ASARCO 3Health News:Waves, particles and medicine in Houston 2Health News:New hearing aid technology passes the restaurant noise test 2Health News:New hearing aid technology passes the restaurant noise test 3
Liquichek Cardiac Markers Control is a multi-analyte liquid control for monitoring cardiac assessment tests. Assayed values are available for major instruments....
Meter Trax Control is a whole blood quality control that can be used for glucose, hemoglobin and hematocrit testing on point of care instruments....
Lyphochek Hemoglobin A2 Control is a human whole blood based product designed to monitor the performance of automated and manual procedures for the measurement of hemoglobin variants, including Hemog...
Liquichek Hematology Control (A) is an assayed hematology control for evaluating the performance of Abbott Cell-Dyn 1600, 1700, 3000, 3500 and 3700 analyzers with 5-part differential technology....
Medicine Products: